Compare SCSC & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCSC | OLMA |
|---|---|---|
| Founded | 1992 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 994.9M |
| IPO Year | 1997 | 2020 |
| Metric | SCSC | OLMA |
|---|---|---|
| Price | $55.32 | $11.69 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | $43.00 | ★ $44.89 |
| AVG Volume (30 Days) | 181.2K | ★ 1.5M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 15.00 |
| EPS | ★ 2.42 | N/A |
| Revenue | ★ $3,846,260,000.00 | N/A |
| Revenue This Year | $2.60 | N/A |
| Revenue Next Year | $4.01 | N/A |
| P/E Ratio | $22.26 | ★ N/A |
| Revenue Growth | ★ 7.79 | N/A |
| 52 Week Low | $33.76 | $4.47 |
| 52 Week High | $55.84 | $36.26 |
| Indicator | SCSC | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 65.18 | 49.70 |
| Support Level | $39.23 | $7.79 |
| Resistance Level | N/A | $13.09 |
| Average True Range (ATR) | 1.56 | 0.65 |
| MACD | -0.08 | -0.01 |
| Stochastic Oscillator | 88.10 | 40.76 |
ScanSource Inc provides value-added services for technology manufacturers and sells to resellers in specialty technology markets. The firm's operations are organized in two segments: Specialty Technology Solutions and Intelisys & Advisory Segment. It generates maximum revenue from the Specialty Technology Solutions segment. The Specialty Technology Solutions segment includes the company's business in mobility and barcode, POS, payments, security and networking technologies. Geographically, it derives a majority of revenue from the United States and Canada, and also has its presence in Brazil, and other countries.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.